StockNews.com Initiates Coverage on NeuroMetrix (NASDAQ:NURO)

Analysts at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Friday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Up 1.8 %

NURO opened at $4.50 on Friday. The firm has a market cap of $9.24 million, a P/E ratio of -0.98 and a beta of 2.15. The business’s fifty day simple moving average is $4.34 and its 200 day simple moving average is $4.14. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73.

Institutional Investors Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. GTS Securities LLC bought a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned about 1.12% of NeuroMetrix as of its most recent filing with the Securities and Exchange Commission (SEC). 19.40% of the stock is currently owned by institutional investors and hedge funds.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.